{"id":3825,"date":"2015-10-21T08:27:22","date_gmt":"2015-10-21T08:27:22","guid":{"rendered":"http:\/\/www.mrc.soton.ac.uk\/web2\/?p=3825"},"modified":"2015-10-21T08:27:22","modified_gmt":"2015-10-21T08:27:22","slug":"holroyd-chris-publications","status":"publish","type":"post","link":"https:\/\/generic.wordpress.soton.ac.uk\/mrclec\/2015\/10\/21\/holroyd-chris-publications\/","title":{"rendered":"Holroyd, Chris – Publications"},"content":{"rendered":"

[vc_row][vc_column][vc_column_text el_class=”reflist”]<\/p>\n

2016<\/h2>\n

1) Chan, C. K., Holroyd, C. R., Mason, A., Zarroug, J. and Edwards, C. J. (2016). “Are there dangers in biologic dose reduction strategies?”<\/b> Autoimmunity Reviews<\/u> 15(7): 742-746.<\/p>\n

2) Fong, W., Holroyd, C., Davidson, B., Armstrong, R., Harvey, N., Dennison, E., et al. (2016). “The effectiveness of a real life dose reduction strategy for tumour necrosis factor inhibitors in ankylosing spondylitis and psoriatic arthritis.”<\/b> Rheumatology<\/u> 55(10): 1837-1842.<\/p>\n

3) Holroyd, C. R., Osmond, C., Barker, D. J., Ring, S. M., Lawlor, D. A., Tobias, J. H., et al. (2016). “Placental Size Is Associated Differentially With Postnatal Bone Size and Density.”<\/b> Journal of Bone & Mineral Research<\/u> 31(10): 1855-1864.<\/p>\n

4) Sammut, L., Wallis, D. and Holroyd, C. (2016). “Progressive multifocal leukoencephalopathy associated with infliximab.”<\/b> Journal of the Royal College of Physicians of Edinburgh<\/u> 46(3): 163-165.<\/p>\n

2015<\/h2>\n

1) Marks, J. L., Holroyd, C. R., Dimitrov, B. D., Armstrong, R. D., Calogeras, A., Cooper, C., et al. (2015). “Does combined clinical and ultrasound assessment allow selection of individuals with rheumatoid arthritis for sustained reduction of anti-tumor necrosis factor therapy?”<\/b> Arthritis Care Res (Hoboken)<\/u> 67(6): 746-753.<\/p>\n

2014<\/h2>\n

1) Harvey, N. C., Holroyd, C., Ntani, G., Javaid, K., Cooper, P., Moon, R., et al. (2014). “Vitamin D supplementation in pregnancy: a systematic review.”<\/b> Health Technology Assessment (Winchester, England)<\/u> 18(45): 1-190.<\/p>\n

\u00a0<\/strong><\/p>\n

2012<\/u><\/h2>\n

 <\/p>\n

1) Holroyd, C., Harvey, N., Dennison, E. and Cooper, C. (2012). “Epigenetic influences in the developmental origins of osteoporosis.”<\/strong> Osteoporos.Int.<\/u> 23: 401-410.<\/p>\n

2) Holroyd, C. R., Harvey, N. C., Crozier, S. R., Winder, N. R., Mahon, P. A., Ntani, G., et al. (2012). “Placental size at 19 weeks predicts offspring bone mass at birth: Findings from the Southampton Women’s Survey.”<\/strong> Placenta<\/u> 33: 623-629.<\/p>\n

\u00a0<\/strong><\/p>\n

2011<\/u><\/h2>\n

 <\/p>\n

1) Cooper, C., Cole, Z. A., Holroyd, C. R., Earl, S. C., Harvey, N. C., Dennison, E. M., et al. (2011). “Secular trends in the incidence of hip and other osteoporotic fractures.”<\/strong> Osteoporos.Int<\/u> 22: 1277-1288.<\/p>\n

2) Holroyd, C. R., Cooper, C. and Harvey, N. C. (2011). “Vitamin D and the postmenopausal population.”<\/strong> Menopause.Int.<\/u> 17: 102-107.<\/p>\n

3) Holroyd, C. R. and Harvey, N. C. (2011). “Bone unfriendly drugs.”<\/strong> Osteoporosis Review<\/u> 19(3): 1-6.<\/p>\n

\u00a0<\/strong><\/p>\n

2010<\/u><\/h2>\n

 <\/p>\n

1) Earl, S., Cole, Z. A., Holroyd, C., Cooper, C. and Harvey, N. C. (2010). “Session 2: Other diseases: Dietary management of osteoporosis throughout the life course.”<\/strong> Proc.Nutr.Soc.<\/u> 69: 25-33.<\/p>\n

2) Holroyd, C. R., Davies, J. H., Taylor, P., Jameson, K., Rivett, C., Cooper, C., et al. (2010). “Reduced cortical bone density with normal trabecular bone density in girls with Turner syndrome.”<\/strong> Osteoporos.Int<\/u> 21: 2093-2099.<\/p>\n

\u00a0<\/strong><\/p>\n

2008<\/u><\/h2>\n

 <\/p>\n

1) Holroyd, C., Cooper, C. and Dennison, E. (2008). “Epidemiology of osteoporosis.”<\/strong> Best.Pract.Res.Clin.Endocrinol Metab<\/u> 22: 671-685.[\/vc_column_text][\/vc_column][\/vc_row]<\/p>\n","protected":false},"excerpt":{"rendered":"

[vc_row][vc_column][vc_column_text el_class=”reflist”] 2016 1) Chan, C. K., Holroyd, C. R., Mason, A., Zarroug, J. and Edwards, C. J. (2016). “Are there dangers in biologic dose reduction strategies?” Autoimmunity Reviews 15(7): 742-746. 2) Fong, W., Holroyd, C., Davidson, B., Armstrong, R., Harvey, N., Dennison, E., et al. (2016). “The effectiveness of a real life dose reduction […]<\/p>\n","protected":false},"author":5281,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[6],"tags":[],"class_list":["post-3825","post","type-post","status-publish","format-standard","hentry","category-publications"],"jetpack_featured_media_url":"","_links":{"self":[{"href":"https:\/\/generic.wordpress.soton.ac.uk\/mrclec\/wp-json\/wp\/v2\/posts\/3825","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/generic.wordpress.soton.ac.uk\/mrclec\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/generic.wordpress.soton.ac.uk\/mrclec\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/generic.wordpress.soton.ac.uk\/mrclec\/wp-json\/wp\/v2\/users\/5281"}],"replies":[{"embeddable":true,"href":"https:\/\/generic.wordpress.soton.ac.uk\/mrclec\/wp-json\/wp\/v2\/comments?post=3825"}],"version-history":[{"count":0,"href":"https:\/\/generic.wordpress.soton.ac.uk\/mrclec\/wp-json\/wp\/v2\/posts\/3825\/revisions"}],"wp:attachment":[{"href":"https:\/\/generic.wordpress.soton.ac.uk\/mrclec\/wp-json\/wp\/v2\/media?parent=3825"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/generic.wordpress.soton.ac.uk\/mrclec\/wp-json\/wp\/v2\/categories?post=3825"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/generic.wordpress.soton.ac.uk\/mrclec\/wp-json\/wp\/v2\/tags?post=3825"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}